

HER2 nanobody (RAD201) demonstrates favourable tumor targeting in breast cancer patients

Sydney, Australia – 13 December 2022 – Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce positive imaging data has been published regarding its HER2 nanobody (RAD201) in the prestigious European Journal of Nuclear Medicine & Molecular Imaging.

The publication indicated that RAD201 has a favourable biodistribution and showed high accumulation in all active HER2 positive tumor sites. It demonstrated a high target-to-background ratio, favourable tumor targeting and rapid blood clearance.

The publication also supports previous data regarding the safety profile for use of RAD201 in humans.

In conclusion, the publication highlighted that RAD201 is a ‘promising non-invasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment’. This is made possible due to RAD201’s ability to bind to a different part of the HER2 receptor.

The full publication is available to view at: <https://link.springer.com/article/10.1007/s00259-022-06066-3>

Radiopharm’s Chief Executive Officer & Managing Director, Riccardo Canevari, said: “This is an outstanding endorsement of our RAD201 technology that gives us added confidence to develop this asset even further.

“HER2 positive breast cancer is around 15-20% of all breast cancer cases, is particularly aggressive and hence has a higher mortality rate. Any new imaging or therapeutic solutions that can make a difference for this disease are highly sought after.”

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

**ASX ANNOUNCEMENT
13 DECEMBER 2022**



Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>